RGT-419B

Phase 1Small molecule

RRegor Pharmaceuticals Inc.

RGT-419B is one of 28 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

RGT-419B

RRegor Pharmaceuticals Inc.

Phase 1

2 6

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Breast Cancer

NCT06299124

Q1 2027

Phase 1Recruiting

Breast Cancer

NCT05304962

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Phase I Study Evaluating Safety and Tolerability of RGT-419B Monotherapy in Chinese Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer or Other Solid Tumors

Active, not recruiting·RRegor Pharmaceuticals Inc.·Phase 1·NCT06299124·40 enrolled

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Recruiting·RRegor Pharmaceuticals Inc.·Phase 1·NCT05304962·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RGT-419B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RGT-419B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RGT-419B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regor Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRegor Pharmaceuticals Inc.

RGT-419B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Breast Cancer2 trials

References

Drug Info

Quick Facts

Related News